<DOC>
	<DOCNO>NCT00002590</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat child lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate toxicity feasibility intensify New York I ( NYI ) regimen add etoposide cytarabine , increase dose methotrexate , use pegaspargase , compress treatment duration ( 11 month ) previously untreated child disseminate anaplastic ( Ki-1 positive ) large cell large cell T-cell lymphoma . II . Provide preliminary data future phase III study compare intensified regimen high-risk ALL regimen NYI child disseminate lymphoblastic lymphoma . III . Continue investigate immunophenotype , cytogenetics , molecular biology lymphoblastic lymphoma relationship leukemia . IV . Obtain preliminary data treatment anaplastic large cell ( Ki-1 ) T-cell large cell lymphoma treat intensive NYI . OUTLINE : Patients CNS disease diagnosis receive craniospinal irradiation Regimen A conclusion Maintenance chemotherapy . The following acronym use : ARA-C Cytarabine , NSC-63878 CF Leucovorin calcium , NSC-3590 CTX Cyclophosphamide , NSC-26271 DNR Daunorubicin , NSC-82151 DOX Doxorubicin , NSC-123127 G-CSF Granulocyte Colony-Stimulating Factor ( Amgen ) , NSC-614629 MTX Methotrexate , NSC-740 PEG-ASP Pegaspargase , NSC-624239 PRED Prednisone , NSC-10023 TG Thioguanine , NSC-752 VCR Vincristine , NSC-67574 VP-16 Etoposide , NSC-141540 Induction : 5-Drug Combination Systemic Chemotherapy Hematopoietic Stimulation plus 2-Drug Combination Intrathecal Chemotherapy . VCR/PRED/CTX/DNR/PEG-ASP ; G-CSF ; plus IT ARA-C/IT MTX . Consolidation : 7-Drug Combination Systemic Chemotherapy Hematopoietic Stimulation plus Single-Agent Intrathecal Chemotherapy . VCR/PRED/PEG-ASP/VP-16/TG/ARA-C/MTX/CF ; G-CSF ; plus IT MTX . Maintenance : Sequential Pulses 2- , 3- , 3- , 2-Drug Systemic Chemotherapy Combinations plus Single-Agent Intrathecal Chemotherapy . CTX/TG/IT MTX ; VCR/PRED/DOX ; VCR/MTX/CF/PEG-ASP ; ARA-C/VP-16 . Regimen A : Radiotherapy . Craniospinal irradiation use megavoltage equipment . PROJECTED ACCRUAL : 40 patient enter approximately 10 month . If 4 toxic death occur first 15 patient 5 toxic death occur first 30 patient , accrual stop . As 05/96 , asparaginase replace pegaspargase ; 15-25 additional patient accrue . As 01/97 , maximum 35 patient accrue PEG asparaginase-containing treatment regimen . As 5/97 , study open patient anaplastic large cell T cell large cell lymphoma . Approximately 60-90 patient accrue .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm previously untreated anaplastic large cell Ki1 lymphoma Tcell large cell lymphoma Malignant lymphoblasts ( identified immunophenotype ) pleural fluid , ascitic fluid , bone marrow sufficient diagnosis Large cell lymphoma Tcell phenotype eligible Localized mediastinal disease bone lymphoma eligible CNS disease eligible define : Any clearly identifiable tumor cell cerebral spinal fluid Cranial nerve palsy ( explain extra cranial tumor ) Clinical Spinal Cord Compression Isolated intra cerebral mass No cranial nerve palsy require immediate CNS irradiation PATIENT CHARACTERISTICS : Age : Under 21 Performance status : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : Shortening fraction great 27 % echocardiogram ( ECHO ) OR Left ventricular ejection fraction great 47 % radionuclide scan ( RCNA ) OR Cardiac function assess within normal limit cardiologist ECHO RCNA obtain close clinically possible start therapy PRIOR CONCURRENT THERAPY : No prior therapy except emergency treatment airway obstruction superior vena cava syndrome No 72 hour emergency radiotherapy steroid initiation protocol therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
</DOC>